Analyst Price Targets — CGEM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 11, 2026 12:09 pm | — | Wedbush | $36.00 | $14.31 | TheFly | Cullinan Therapeutics price target raised to $36 from $34 at Wedbush |
| March 10, 2026 1:18 pm | Alex Thompson | Stifel Nicolaus | $28.00 | $15.11 | StreetInsider | Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Stifel |
| February 2, 2026 12:19 am | — | Guggenheim | $30.00 | $11.96 | TheFly | Cullinan Therapeutics initiated with a Buy at Guggenheim |
| January 8, 2026 2:44 pm | — | H.C. Wainwright | $27.00 | $10.77 | TheFly | Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright |
| January 8, 2026 12:38 pm | — | Morgan Stanley | $30.00 | $10.94 | TheFly | Cullinan Therapeutics price target raised to $30 from $28 at Morgan Stanley |
| December 9, 2025 1:13 pm | Robert Driscoll | Wedbush | $34.00 | $12.18 | TheFly | Cullinan Therapeutics price target raised to $34 from $25 at Wedbush |
| November 24, 2025 4:42 pm | Julian Harrison | BTIG | $38.00 | $11.90 | TheFly | Cullinan Therapeutics price target raised to $38 from $32 at BTIG |
| November 20, 2025 3:56 pm | — | New Street | $26.00 | $8.92 | TheFly | Cullinan Therapeutics price target raised to $26 from $24 at H.C. Wainwright |
| October 24, 2024 3:46 am | David Dai | UBS | $30.00 | $15.61 | StreetInsider | UBS Starts Cullinan Oncology Inc. (CGEM) at Buy |
| August 8, 2024 11:56 am | Jeffrey Hung | Morgan Stanley | $38.00 | $16.38 | StreetInsider | Cullinan Oncology Inc. (CGEM) PT Lowered to $38 at Morgan Stanley |
Latest News for CGEM
Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations. Analyst Recommendations This is a breakdown of recent
Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners' Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentially "defining year" driven by multiple clinical readouts across its pipeline. Chief Executive Officer Nadim and Chief Medical Officer Jeff highlighted two "high-priority" T-cell engager (TCE) programs-CLN-978 in…
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed with top-line results available by year-end 2026 Cash and investments of $439.0 million as of December 31, 2025; runway into 2029 CAMBRIDGE, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Cullinan…
Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the company's two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen Healthcare Conference, pointing to multiple data readouts in autoimmune disease in 2026 and an expansion plan for its acute myeloid leukemia (AML) program. Management frames 2026 as a catalyst year President
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $223,109.22. Following the transaction, the chief executive officer directly owned 404,318 shares in
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CGEM.
U.S. House Trading
No House trades found for CGEM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.